atorvastatin has been researched along with paclitaxel in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 7 (70.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Bao, L; Han, J; Liu, H; Ma, K; Wang, K; Wang, W; Xiong, W; Yin, W | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Aohara, F; Fujimura, Y; Harakawa, N; Hasegawa, R; Katori, N; Kim, SR; Maekawa, K; Naito, M; Niwa, T; Okuda, H; Sai, K; Saito, Y; Sawada, J; Tohkin, M; Yoshimura, T | 1 |
Chello, M; Coccia, R; Covino, E; De Marco, F; Di Domenico, F; Di Sciascio, G; Lusini, M; Patti, G; Pettinari, M; Pollari, F; Spadaccio, C; Zanzonico, R | 1 |
Krishnan, UM; Roopmani, P | 1 |
Hammer, HS; Khalaf, S; Kroetz, DL; Mortensen, C; Nielsen, F; Poetz, O; Rodriguez-Antona, C; Stage, TB; Steffensen, V; Svenningsen, ÅF; Xiong, C | 1 |
1 review(s) available for atorvastatin and paclitaxel
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
9 other study(ies) available for atorvastatin and paclitaxel
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Lanostane Triterpenes from the Tibetan Medicinal Mushroom Ganoderma leucocontextum and Their Inhibitory Effects on HMG-CoA Reductase and α-Glucosidase.
Topics: Acyl Coenzyme A; Agaricales; alpha-Glucosidases; Fruiting Bodies, Fungal; Ganoderma; Glycoside Hydrolase Inhibitors; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Inhibitory Concentration 50; K562 Cells; Molecular Structure; Paclitaxel; Tibet; Triterpenes | 2015 |
CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.
Topics: Alleles; Animals; Asia, Eastern; Atorvastatin; Biocatalysis; Camptothecin; Carbamazepine; Cytochrome P-450 CYP3A; Docetaxel; Heptanoic Acids; Humans; Irinotecan; Midazolam; Models, Molecular; Paclitaxel; Pyrroles; Spodoptera; Substrate Specificity; Taxoids; Terfenadine | 2010 |
Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study).
Topics: Aged; Angina, Stable; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Restenosis; Diabetes Complications; Drug-Eluting Stents; Female; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; ROC Curve; Tubulin Modulators | 2013 |
Harnessing the pleiotropic effects of atorvastatin-fenofibrate combination for cardiovascular stents.
Topics: Animals; Atorvastatin; Calorimetry, Differential Scanning; Cell Adhesion; Cell Line; Cell Proliferation; Cell Survival; Drug-Eluting Stents; Fenofibrate; Flow Cytometry; Human Umbilical Vein Endothelial Cells; Humans; Mice; Myocytes, Smooth Muscle; Paclitaxel; Platelet Adhesiveness; Sirolimus; Spectroscopy, Fourier Transform Infrared; Tensile Strength | 2018 |
P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.
Topics: Antineoplastic Agents, Phytogenic; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin; Verapamil | 2020 |